CAS 1047644-62-1

Afuresertib

Description:

Afuresertib is a small molecule inhibitor primarily targeting the protein kinase AKT, which plays a crucial role in various cellular processes, including metabolism, proliferation, and survival. It is classified as a selective inhibitor, demonstrating potential therapeutic applications in oncology, particularly for cancers with aberrant AKT signaling pathways. The compound is characterized by its ability to interfere with the phosphorylation of downstream targets of AKT, thereby inhibiting tumor growth and promoting apoptosis in cancer cells. Afuresertib is typically administered in a clinical setting, and its efficacy is often evaluated in combination with other therapeutic agents. The substance is known for its moderate solubility in organic solvents and has a specific molecular structure that contributes to its biological activity. As with many targeted therapies, the pharmacokinetics and pharmacodynamics of Afuresertib are critical for determining its clinical utility, including its absorption, distribution, metabolism, and excretion profiles. Ongoing research continues to explore its potential in various cancer types and its role in personalized medicine approaches.

GSK-2110183C

CAS: 1047644-62-1

Formula: C₁₈H₁₇Cl₂FN₄OS

Purity: 99%

Color and Shape: Solid

Molecular weight: 427.3232

Ref: IN-DA008TDA

Afuresertib

CAS: 1047644-62-1

Afuresertib

Formula: C₁₈H₁₇Cl₂FN₄OS

Purity: ≥95%

Molecular weight: 427.32

Ref: 54-BUP07169

Afuresertib

CAS: 1047644-62-1

Afuresertib (GSK2110183) is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic

Formula: C₁₈H₁₇Cl₂FN₄OS

Purity: 97.51% - 99.51%

Color and Shape: Solid

Molecular weight: 427.32

Ref: TM-T1911

Afuresertib

CAS: 1047644-62-1

Inhibitor of pan-AKT

Formula: C₁₈H₁₇Cl₂FN₄OS

Purity: Min. 95%

Molecular weight: 427.32 g/mol

Ref: 3D-BA166066